Contribution of myeloid-derived suppressor cells to tumor-induced immune suppression, angiogenesis, invasion and metastasis

https://doi.org/10.1016/S1673-8527(09)60061-8Get rights and content

Abstract

Growing evidence suggests that myeloid-derived suppressor cells (MDSCs), which have been named “immature myeloid cells” or “myeloid suppressor cells” (MSCs), play a critical role during the progression of cancer in tumor-bearing mice and cancer patients. As their name implies, these cells are derived from bone marrow and have a tremendous potential to suppress immune responses. Recent studies indicated that these cells also have a crucial role in tumor progression. MDSCs can directly incorporate into tumor endothelium. They secret many pro-angiogenic factors as well. In addition, they play an essential role in cancer invasion and metastasis through inducing the production of matrix metalloproteinases (MMPs), chemoattractants and creating a pre-metastatic environment. Increasing evidence supports the idea that cancer stem cells (CSCs) are responsible for tumorigenesis, resistance to therapies, invasion and metastasis. Here, we hypothesize that CSCs may “hijack” MDSCs for use as alternative niche cells, leading to the maintenance of stemness and enhanced chemo- and radio-therapy resistance. The countermeasure that directly targets to MDSCs may be useful for against angiogenesis and preventing cancer from invasion and metastasis. Therefore, the study of MDSCs is important to understand tumor progression and to enhance the therapeutic efficacy against cancer.

References (79)

  • S. Penuelas et al.

    TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma

    Cancer Cell

    (2009)
  • P.C. Rodriguez et al.

    L-arginine availability regulates T-lymphocyte cell-cycle progression

    Blood

    (2007)
  • S. Sakaguchi

    Regulatory T cells: key controllers of immunologic self-tolerance

    Cell

    (2000)
  • Y. Sawanobori et al.

    Chemokine-mediated rapid turnover of myeloid-derived suppressor cells in tumor-bearing mice

    Blood

    (2008)
  • L. Yang et al.

    Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis

    Cancer Cell

    (2004)
  • L. Yang et al.

    Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis

    Cancer Cell

    (2008)
  • K. Arai et al.

    S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr

    Cancer Drug Targets

    (2008)
  • D. Belotti et al.

    Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation

    Cancer Res.

    (2003)
  • V. Bronte et al.

    Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers

    J. Exp. Med.

    (2005)
  • S.K. Bunt et al.

    Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression

    J. Immunol.

    (2006)
  • L.S. Cauley et al.

    Superantigen-induced CD4 T cell tolerance mediated by myeloid cells and IFN-gamma

    J. Immunol.

    (2000)
  • C.E. Clark et al.

    Dynamics of the immune reaction to pancreatic cancer from inception to invasion

    Cancer Res.

    (2007)
  • M.F. Clarke et al.

    Cancer stem cells—perspectives on current status and future directions: AACR Workshop on cancer stem cells

    Cancer Res.

    (2006)
  • R.A. Dean et al.

    Identification of candidate angiogenic inhibitors processed by matrix metalloproteinase 2 (MMP-2) in cell-based proteomic screens: disruption of vascular endothelial growth factor (VEGF)/heparin affin regulatory peptide (pleiotrophin) and VEGF/Connective tissue growth factor angiogenic inhibitory complexes by MMP-2 proteolysis

    Mol. Cell Biol.

    (2007)
  • M.V. Dhodapkar et al.

    Interactions of tumor cells with dendritic cells: balancing immunity and tolerance

    Cell Death Differ.

    (2008)
  • M. Friedlander et al.

    Progenitor cells and retinal angiogenesis

    Angiogenesis

    (2007)
  • D. Gabrilovich

    Mechanisms and functional significance of tumour-induced dendritic-cell defects

    Nat. Rev. Immunol.

    (2004)
  • D.I. Gabrilovich et al.

    Myeloid-derived suppressor cells as regulators of the immune system

    Nat. Rev. Immunol.

    (2009)
  • D.I. Gabrilovich et al.

    Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

    Nat. Med.

    (1996)
  • R.J. Gilbertson et al.

    Making a tumour's bed: glioblastoma stem cells and the vascular niche

    Nat. Rev. Cancer

    (2007)
  • S. Hiratsuka et al.

    Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis

    Nat. Cell Biol.

    (2006)
  • B. Huang et al.

    Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host

    Cancer Res.

    (2006)
  • L.C. Huysentruyt et al.

    Metastatic cancer cells with macrophage properties: evidence from a new murine tumor model

    Int. J. Cancer

    (2008)
  • D. Ilkovitch et al.

    The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression

    Cancer Res.

    (2009)
  • D.K. Jin et al.

    Cytokine-mediated deployment of SDF-1 induces revascularization through recruitment of CXCR4+ hemangiocytes

    Nat. Med.

    (2006)
  • R.S. Kerbel et al.

    Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches

    Cancer Metastasis Rev.

    (2001)
  • T. Kitamura et al.

    SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion

    Nat. Genet.

    (2007)
  • M. Kujawski et al.

    Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice

    J. Clin. Invest.

    (2008)
  • S.S. Lakka et al.

    Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis

    Oncogene

    (2004)
  • Cited by (68)

    • Hypoxia, a key factor in the immune microenvironment

      2022, Biomedicine and Pharmacotherapy
    • Immunobiology of Melanoma

      2021, Clinics in Plastic Surgery
    • The impact of microRNAs on myeloid-derived suppressor cells in cancer

      2021, Human Immunology
      Citation Excerpt :

      These were previously described to initiate additional immunosuppressive mechanisms of MDSCs [29]. Also, there is increasing evidence that MDSCs are activated, and stimulated by tumor-derived agents that mainly function in tumor expansion, angiogenesis, and metastasis [26,30]. These cells are established to secrete basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) to endorse tumor neovascularization [31].

    • Expansion of PMN-myeloid derived suppressor cells and their clinical relevance in patients with oral squamous cell carcinoma

      2019, Oral Oncology
      Citation Excerpt :

      Therefore, the identification of the mechanisms underlying the immune dysfunction associated with aggressive tumor growth and treatment responses is important for the effective management of OSCC. Myeloid-derived suppressor cells (MDSCs) are immune-suppressive cells with the ability to suppress T cell activation and function [7-9]. MDSCs were initially investigated in malignant diseases based on their important role in the regulation of immune responses in patients with tumors.

    View all citing articles on Scopus
    View full text